Medicenna Therapeutics Corp ( (TSE:MDNA) ) has provided an update.
Medicenna Therapeutics Corp has announced promising results from its ABILITY-1 study, showcasing the potential of its MDNA11 therapy in combination with Merck’s KEYTRUDA® for treating advanced solid tumors. The study revealed that MDNA11 significantly expands stem-like CD8+ T cells, leading to a 30% objective response rate in checkpoint-resistant patients and a 78% disease control rate when combined with KEYTRUDA®. These findings suggest that MDNA11 could enhance the efficacy of immune checkpoint inhibitors and improve outcomes for patients with difficult-to-treat cancers.
More about Medicenna Therapeutics Corp
Medicenna Therapeutics Corp is a clinical-stage immunotherapy company focused on the development of Superkines, which are engineered cytokines designed to enhance the immune system’s ability to fight cancer. The company is involved in the research and development of innovative therapies for cancer treatment, with a particular emphasis on leveraging the unique properties of stem-like CD8+ T cells to improve patient outcomes.
YTD Price Performance: -28.93%
Average Trading Volume: 70,293
Technical Sentiment Consensus Rating: Buy
Current Market Cap: C$88.38M
For detailed information about MDNA stock, go to TipRanks’ Stock Analysis page.